GlassScriptPhysician profile
Curtis Hayden
NPI 1760588248
$4,753.33
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,812 · 2020: $672 · 2021: $1,492 · 2022: $465 · 2023: $189 · 2024: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $311.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $567.87 | 2019-2022 | |
| Lundbeck LLC | $349.53 | 2021-2024 | Vyepti |
| Jazz Pharmaceuticals INC. | $324.22 | 2019-2023 | Xywav |
| Mallinckrodt Enterprises LLC | $306.09 | 2019 | |
| Mallinckrodt Hospital Products INC. | $304.37 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $249.36 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $249.02 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $219.77 | 2022 | |
| Neurocrine Biosciences, INC. | $205.01 | 2021 | |
| Abbvie INC. | $196.45 | 2021-2022 | |
| Amgen INC. | $185.46 | 2019-2020 | |
| Emd Serono, INC. | $175.51 | 2019 | |
| Alexion Pharmaceuticals, INC. | $158.87 | 2019-2020 | |
| Sk Life Science, INC. | $148.39 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $145.29 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $144.46 | 2019 | |
| Allergan, INC. | $140.98 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $119.83 | 2019 | |
| Lilly USA, LLC | $118.79 | 2019-2022 | |
| Nuvasive, INC. | $115.38 | 2019 | |
| Grifols USA, LLC | $88.74 | 2019 | |
| Livanova USA, INC. | $65.47 | 2020-2022 | |
| Biogen, INC. | $40.57 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.02 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $21.73 | 2022 | |
| Corium, LLC | $19.82 | 2022 | |
| Upsher-Smith Laboratories LLC | $17.92 | 2021 | |
| Genentech USA, INC. | $13.82 | 2021 | |
| Neurelis, INC. | $13.57 | 2020 | |
| Assertio Therapeutics, INC. | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Hayden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.